GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » EBITDA Margin %

ALT (Altimmune) EBITDA Margin % : -456,040.00% (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Altimmune EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Altimmune's EBITDA for the three months ended in Sep. 2024 was $-22.80 Mil. Altimmune's Revenue for the three months ended in Sep. 2024 was $0.01 Mil. Therefore, Altimmune's EBITDA margin for the quarter that ended in Sep. 2024 was -456,040.00%.


Altimmune EBITDA Margin % Historical Data

The historical data trend for Altimmune's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune EBITDA Margin % Chart

Altimmune Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -348.03 -660.02 -2,188.98 124,130.88 -20,642.02

Altimmune Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,669.89 -85,202.70 -485,720.00 -491,560.00 -456,040.00

Competitive Comparison of Altimmune's EBITDA Margin %

For the Biotechnology subindustry, Altimmune's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Altimmune's EBITDA Margin % falls into.



Altimmune EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Altimmune's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-87.935/0.426
=-20,642.02 %

Altimmune's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-22.802/0.005
=-456,040.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altimmune  (NAS:ALT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Altimmune EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Altimmune's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Altimmune Business Description

Traded in Other Exchanges
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Executives
David Drutz director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Catherine A. Sohn director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Matthew Scott Harris officer: Chief Medical Officer C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt officer: Chief Business Officer ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg director, officer: President and CEO 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill director C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts officer: Chief Scientific Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges director 19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018